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Abstract
Objectives—Evaluate the impact of obstructive sleep apnea (OSA) on neurocognitive function 
and brain morphology in older adults with depression and cognitive impairment.
Methods—We prospectively screened OSA with the STOP-Bang questionnaire in the last 25 
patients enrolled into the Donepezil Treatment of Cognitive Impairment and Depression 
(DOTCODE) trial. High and low probability of OSA were defined as a STOP-Bang score of ≥5 
(h-OSA) and of <5 (l-OSA). Baseline MRI was used to evaluate brain morphology. The initial 16 
weeks of antidepressant treatment were part of the DOTCODE trial.
Results—After 16 weeks of antidepressant treatment, the h-OSA group performed significantly 
worse on the Selective Reminding Test (SRT) delayed recall task than the l-OSA group, 
controlling for baseline performance (F=19.1, df=1,22, p<0.001). In nineteen out of 25 
participants who underwent brain MRI, the h-OSA group had significantly greater volumes of 
MRI hyperintensities in deep white matter, periventricular white matter, and subcortical gray 
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matter compared to the l-OSA group. There was no significant association between OSA and 
hippocampal or entorhinal cortex volumes in our sample, even after controlling for intracranial 
volume.
Conclusions—OSA is associated with impaired verbal episodic memory and microvascular 
damage in older adults with depression and cognitive impairment. One possibility is that by 
contributing to cerebral microvascular damage, OSA may exacerbate progressive memory decline.
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INTRODUCTION
Obstructive sleep apnea (OSA) is caused by repeated partial or complete upper airway 
collapse, despite an ongoing effort to breathe during sleep. It is estimated that 22 million 
Americans suffer from OSA, including 24% of men and 9% of women in the middle-aged 
population (aged 30–60 years),1 and 40%–60% of older adults (aged 65+ years).2 
Epidemiological studies consistently report a high prevalence of depression among 
individuals with OSA.3–5 The exact prevalence of cognitive impairment associated with 
OSA is difficult to estimate. Results from two independent meta-analysis studies provided 
evidence that individuals with OSA were significantly impaired on attention/vigilance, 
executive function, and verbal episodic memory.6,7 Emerging evidence demonstrates that 
older adults with OSA may be at greater risk of developing cognitive impairment or 
Alzheimer’s disease (AD) compared with age- and sex-matched healthy controls.8,9 Current 
structural imaging data suggest that hippocampal atrophy and microvascular damage (e.g., 
white matter hyperintensities, white matter integrity abnormalities, and gray matter loss), are 
accompanied by OSA,10–12 although a few studies failed to identify such structural 
changes.13,14
Late-life depression and cognitive impairment are the most common neuropsychiatric 
disorders in the older adult populations. We reported the first epidemiological data showing 
that depression was associated with an increased risk of converting to AD during a 3-year 
follow-up period (RR=2.9, 95% CI, 1.76–4.91, P < .001).15 A meta-analysis suggested that 
depression was an independent risk factor for AD.16 Conversely, a recent epidemiological 
study revealed that the association of depression with prevalent dementia and with 
progression from MCI to dementia was stronger for vascular dementia than for AD.17 
Whether depression shares common pathologic mechanisms with AD-related pathology 
remains controversial.18,19 On the other hand, a large body of imaging research has 
demonstrated the vascular and neural bases for these disorders. While OSA is known for its 
destructive nature in the cerebral vascular and neural systems, whether OSA plays an 
important role in the cognitive deteriorating process in older adults with amnestic MCI 
(aMCI) and depression is not clear. No study to date has evaluated the impact of OSA in this 
population.
As a sub-study in the Donepezil Treatment of Older Adults with Cognitive Impairment and 
Depression trial (DOTCODE, NCT01658228),20 we used the widely validated STOP-Bang 
Kerner et al. Page 2













questionnaire21 as an add-on instrument to assess the probability of OSA. Using standard 
methods, a score of ≥ 5 was defined as a high probability of OSA (h-OSA) while a score of 
< 5 was defined as a low probability of OSA (l-OSA).22–25 We examined 1) baseline brain 
morphology, specifically microvascular damage and regions of interest (hippocampus and 
entorhinal cortex), which play critical roles in predicting conversion to dementia, and 2) 
changes in cognitive performance following 16 weeks of open antidepressant treatment 
(DOTCODE phase 1). We hypothesized that participants with h-OSA would exhibit more 
severe microvascular damage and poorer cognitive performance, particularly verbal episodic 
memory (primary outcome measure), than those with l-OSA.
METHODS
Participants
This study consisted of the last 25 participants enrolled to the DOTCODE trial20 at the Late-
life Depression and Memory Disorders Clinics at New York State Psychiatric Institute 
(NYSPI). Participants were eligible for this add-on study if they met the inclusion/exclusion 
criteria for the DOTCODE trial. Salient Inclusion criteria included age 55–95 years old, 
study criteria for cognitive impairment as measured by 1) subjective memory or other 
cognitive complaints and 2) Score of ≤ 11 on the Logical Memory II (Delayed Paragraph 
Recall, Paragraph A) test from the Wechsler Memory Scale – Revised (WMSR)26 OR a 
score 1.5 SD or more below norms on the Free and Cued Selective Reminding Test (FC-
SRT)27 immediate or delayed recall, Folstein Mini Mental State Exam28 (MMSE) score of ≥ 
21 out of 30, and study criteria for depression that required DSM-IV symptom criteria for 
Major Depression or Dysthymic Disorder for a minimum of 6 months (2 year duration 
DSM-IV TR criterion not required for dysthymic disorder in this study) and a 24-item 
Hamilton Rating Scale of Depression (HRSD)29 score ≥ 14. Salient exclusion criteria 
included clinical stroke with residual neurological deficits, DSM-IV criteria for dementia or 
probable Alzheimer’s disease (NINCDS-ADRDA criteria), DSM-IV TR criteria for a) 
schizophrenia, schizoaffective disorder, psychotic depression, bipolar disorder or other 
psychosis, alcohol or substance dependence or abuse (current or within past 6 months), 
active suicidal ideation or suicidal attempt in the last 6 months, or an acute, severe or 
unstable medical condition at the evaluation visit. Participants who were taking 
benzodiazepines in lorazepam equivalents ≥ 2 mg daily, narcotics, or anticholinergics were 
ineligible to participate because these medications are known to have a negative impact on 
cognition. Participants taking warfarin or monoamine oxidase inhibitors (MAOIs) were also 
ineligible to participate. Brain research MRI scan was optional and done at baseline. All 
DOTCODE participants were required to have the capacity to provide informed consent and 
sign the IRB-approved informed consent form. Local IRB and State regulations for consent 
were followed. The IRB of NYSPI at CUMC approved this add-on pilot study.
Treatment
The DOTCODE trial Phase 1 consisted of an open antidepressant treatment phase (initial 16 
weeks). Participants first underwent an 8-week treatment period with the selective serotonin 
reuptake inhibitor citalopram, starting with 10mg/day for the first week, then increasing to 
20mg/day thereafter. At the week 8 visit, citalopram responders (those with a 50% reduction 
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from baseline HRSD) were instructed to continue citalopram treatment, and participants 
who failed to respond to citalopram began an 8-week venlafaxine treatment period, starting 
with 37.5mg/day for the first week, then increasing to 225mg/day for the fifth to eighth 
week. If deemed clinically necessary by the study physician, 300mg/day was prescribed. At 
the end of the eighth week, venlafaxine responders (those with a 50% reduction from 
baseline HRSD) were instructed to continue venlafaxine treatment. At the end of the 
sixteenth week, non-responders to both citalopram and venlafaxine received antidepressant 
based on the doctor’s choice in consultation with the patient. A flexible dosing schedule was 
employed throughout the study, based on the physician’s assessment of the efficacy and 
tolerability of the medication. Phase 2 was not part of this pilot sub-study. Protocol details 
have been published elsewhere.20
Measures
OSA—OSA severity is determined by number of apneas and hypopneas per hour of sleep 
(apnea/hypopnea index, AHI) and is usually categorized as: mild (AHI of 5–15), moderate 
(AHI of 15–30), and severe (AHI ≥ 30).30 We selected the STOP-Bang scale to assess pre-
test probability of having moderate to severe OSA because it has the highest methodological 
metrics and has shown sensitivity in predicting moderate-severe OSA, as compared to other 
OSA screening questionnaires.31 The STOP-Bang scale consists of eight yes/no question 
items with total scores ranging from 0 to 8, 1-point for each question, including 4 items in 
the STOP (loud Snore, Tired, Observed apnea, and high blood Pressure) category and 4 
items in the BANG (BMI, Age, Neck size, and Gender) category.21 (The sensitivity of 
scores ≥3 to detect moderate and severe OSA is 93–100%, respectively; a STOP-Bang score 
of 5–8 is associated with a high probability of moderate to severe OSA.22 The correlation 
between STOP-Bang score and severity of OSA as diagnosed by PSG has been further 
validated in several studies with large sample sizes.23–25 The STOP-Bang Questionnaire has 
been widely used in the general population, including with medical, surgical, and psychiatric 
patients.32
In this preliminary study, a STOP-Bang score of ≥ 5 was defined as having high probability 
of moderate to severe OSA (the h-OSA group), while a STOP-Bang score of <5 was defined 
as having low probability of moderate to severe OSA (the l-OSA group). Study physicians 
also assessed OSA related medical comorbidities.
Depression—Depressive symptoms were assessed with the 24-item HRSD.
Neuropsychological Evaluation—In addition to the inclusion criteria, we assessed 
other neuropsychological domains. Verbal Episodic Memory (primary outcome measure): 
12-item 6-trial Selective Reminding Test (SRT).33 Processing speed: Trail Making Test-Part 
A (Trail A). Executive Function: Trail Making Test - Part B (Trail B), and WAIS-III Digit 
Symbol34, which also tapped into processing speed. Visual Memory: WMS-III visual 
reproduction subtest (WMS-III; Wechsler, 1997). Language skills: verbal fluency (Letter and 
Animal Naming, 60-second trials).
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MRI—MRI study was part of the DOTCODE trial. MRI was obtained at baseline and 
acquired on a GE Signa 3 Tesla whole body scanner with the following sequences. Three-
Plane Localizer Repetition Time (TR) = 23.4 ms, Echo Time (TE) = 1.7 ms, Flip angle = 
30°, Bandwidth = 31.3 MHz, field of view (FOV) = 24 × 24 cm, thickness = 5.0 mm, 
Spacing = 1.5 mm, 9 slices per volume (3 axials, 3 sagittals, 3 coronals), Matrix 256 × 128. 
Scan Time: 10 second. 3D SPGR Anatomical Sequence TI 500 ms, TR 5 ms, TE Minimum 
(1.3 ms), Flip angle 11°, Band width 31.25 MHz, FOV 26 × 26, Slice thickness 1.1 mm, 
spacing 0.0, 128 slices per volume, 1 NEX images × 2 (acquisitions averaged off line), 
Matrix 256 × 256. This sequence was acquired in the coronal orientation aligned to the long 
axis of the hippocampus, and these nearly isotropic images were easily reformatted into any 
plane for definition of ROIs. T2 FLAIR: 2D IR axial images with TR=10,000 msec, TE=122 
msec, TI=2000 msec, FOV=24, matrix = 320×256, NEX=1, Slice thickness=5 mm, 31 
slices. Scan Time: 4.4 minutes.
Quantification of whole brain MRI signal hyperintensity volume used the MRIcro 
software.35 The procedure has been described in our previously published study.36 We used 
the modified Rating Scale to assess the severity of microvascular lesions.37 Periventricular 
white matter hyperintensity (PVH) was graded as 0 (absent), 1 (“caps,” or pencil-thin 
lining), 2 (smooth “halo”), or 3 (irregular periventricular hyperintensities extending into the 
deep white matter). Deep white matter hyperintensity (DWMH) was graded as 0 (absent), 1 
(punctate foci), 2 (beginning confluence of foci), or 3 (large confluent areas). Subcortical 
gray matter hyperintensity (SCG) was scored as 0 (absent), 1 (punctate), 2 (multipunctate), 
or 3 (diffuse).
Regions of interest (ROIs), chosen a priori, were based on our previously published study 
identifying regions that predicted increased risk of dementia in aMCI.38 The anatomical 
boundaries for hippocampus and entorhinal cortex tracings have been described elsewhere;38 
the interrater and intrarater reliability were 0.90 and 0.92 for hippocampus volume, and 0.98 
and 0.99 for entorhinal cortex volume, respectively. An experienced technician, who was 
trained and maintains reliability with expert raters, rated all scans and drew ROIs using 
atlas-based approaches to define the hippocampus and entorhinal cortex.
Statistical Analysis
All data were analyzed using the Statistical Package for Social Sciences (SPSS version 
23.0). A 5% level was used to determine statistical significance. No adjustments were made 
to account for multiple testing.
Clinical and Neuropsychological data analyses
Patient demographic and clinical features were compared between the h-OSA group and the 
l-OSA-group using chi-square tests (χ2) or Fisher’s exact tests for categorical variables, and 
two-tailed t-tests for continuous variables. Differences in HRSD between the two groups 
were assessed at both baseline and week 16 using t-tests. Change in HRSD within each 
group was assessed using paired t-tests. Difference in changes in HRSD between the two 
groups was assessed by fitting a linear regression model having HRSD at week 16 as the 
outcome with baseline HRSD and OSA group as predictors. We tested the slope coefficient 
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of OSA to assess differences between the groups in changes in HRSD over 16 weeks. To 
assess differences between the two groups on baseline cognitive measures we fit (1) linear 
regression models with each cognitive measure as the outcome and OSA as the predictor and 
(2) the same models, adjusting for baseline HRSD. We tested the slope coefficient for OSA 
in each model to assess differences between the two groups on these baseline measures. To 
assess differences between the two groups on changes in cognitive measures we fit (1) linear 
regression models with each cognitive measure at week 16 as the outcome and had the 
corresponding baseline measure and OSA group as the predictors and (2) the same models, 
adjusting for HRSD at week 16. We tested the slope coefficient for OSA in each model to 
assess differences between the two groups on changes in each cognitive measure over 16 
weeks.
Baseline MRI data analyses
The severity of microvascular lesions was dichotomized into two categories: grade 0–1 and 
grade 2–3 lesions. Associations between the two groups and binary lesion severity were 
assessed using Fisher’s exact test. Differences between the two groups with respect to 
DWMH, PVH, and SCG were assessed using the Mann-Whitney U test. The Mann-Whitney 
U test was also used to assess differences between OSA groups with respect to hippocampal 
volume and entorhinal cortex volume. To control for intracranial volume, we took the ratios 
of hippocampal volume/intracranial volume and entorhinal cortex volume/intracranial 
volume and used the Mann-Whitney U test to assess differences between the two groups 
with respect to these ratios.
RESULTS
Baseline Demographic and Clinical Features
Among 25 participants, there were 10 in the h-OSA group and 15 in the l-OSA group. As 
shown in Table 1, age, education, depression severity, and the MMSE were not significantly 
different between the two groups while body mass index was significantly higher in the h-
OSA group. The h-OSA group had higher proportions of males, hypertension, and vascular 
risk factors than the l-OSA group. No participants received any form of OSA treatment 
before or during this study.
MRI
Nineteen out of 25 participants underwent MRI scan. For volume of MRI hyperintensities 
(See Table 2), we used Mann-Whitney U-test to compare the two groups. The h-OSA group 
had greater volumes of DWMH (Z=2.60, p=0.009), PVH (Z=2.24, p=0.025), and SCG 
(Z=2.28, p=0.023) as compared to the l-OSA group. For microvascular lesion severity, the h-
OSA group had higher proportions of grade 2–3 lesions in DWMH (33% vs. 0%), PVH 
(83.3% vs. 46.2%), and SCG (33% vs. 0%), though the differences were not statically 
significant between the two groups. For volumes of hippocampus and entorhinal cortex, 
there were no statistically significant differences between the two groups, even after 
controlling for intracranial volume.
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At baseline, there was no significant difference in HRSD between the two groups. After 16 
weeks of antidepressant treatment, depression severity significantly improved in both groups 
(h-OSA group: t=7.99, df=9, p<0.001; l-OSA group: t=5.42, df=14, p<0.001). There was no 
difference in depression severity at week 16 between the two groups, even after controlling 
for baseline depression severity.
Neuropsychological Performance
At baseline, there were no statistically significant differences in performance across all 
cognitive domains, including attention/psychomotor, executive function, and verbal memory 
between the two groups and the results remained non-significant after controlling for 
baseline depression severity. As shown in Table 3, performance on executive function tasks 
(Trails B and Digital Symbol) improved in both groups following antidepressant treatment; 
performance on processing speed tasks (Trails A) and verbal episodic memory tasks (SRT 
total and delayed recall) improved in the l-OSA group but worsened in the h-OSA group. 
With the exception of performance on verbal delayed recall tasks, these changes were not 
significantly different between the two groups, even after controlling for both baseline 
cognitive performance and week 16 depressive symptom severity. There was a 1-point 
average decrease in verbal delayed recall in the h-OSA group and a 2-point average increase 
in the l-OSA group (See Figure 1); the difference between the two groups was observed only 
after acute depressive symptoms were treated (F=19.1, df(1,22), p<0.001), and the results 
remained significant after controlling for both baseline performance and week 16 depression 
severity. No participants dropped out or stopped antidepressant treatment during this study 
period.
DISCUSSION
The goals of this add-on preliminary study to the DOTCODE Trial (Phase 1) were to 
investigate the impact of OSA on brain morphology and cognitive performance in older 
adults with both depression and MCI. We found that 1) there was a significant association 
between OSA and severity of microvascular damage as identified on MRI, 2) the association 
between OSA and hippocampal or entorhinal cortex volume was not significant, even after 
controlling for intracranial volume, and 3) following 16 weeks of antidepressant treatment, 
changes in cognitive measures across multiple domains were not statistically significant 
between the groups, with the exception of verbal episodic memory.
As hypothesized, we found that the h-OSA group had significantly greater volumes of 
DWMH, PVH, and SCG, as well as a higher proportion of severe microvascular lesions 
when compared to the l-OSA group. In previous studies, greater white matter damage and 
more advanced microvascular lesions were associated with an increased risk for more rapid 
cognitive decline and new onset of AD in patients with amnestic MCI.39–41 One possible 
explanation for our findings is that OSA may facilitate additional neural injury (e.g., beyond 
that which is seen in AD pathology alone) and accelerate cognitive decline. Consequently, 
cognitive deficits accompanying OSA may persist or progress if OSA is left untreated. 
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Recent imaging studies showed that OSA treatment may lead to improvement in indices of 
microvascular and neural damage, and may result in improved cognitive functioning.
Several studies found that OSA patients had smaller hippocampi than those without 
OSA.10,42 We conducted exploratory analyses on baseline hippocampal volume and 
entorhinal cortical volume and did not find significant differences between the two groups. 
Several possibilities may explain our findings. First, our participants had aMCI at baseline; 
thus, the impact of OSA might not prevail over the effects of AD pathology on hippocampal 
volume in our study sample. Second, the overall effect of OSA on hippocampal volume 
depends on the severity and chronicity of OSA.4344 As such, disentangling the pure effects 
of OSA on hippocampal volume in our participants, whom were likely to have had AD 
pathology, would be difficult. Third, episodic memory impairment could be, in part, the 
result of an indirect effect on hippocampal functioning through remote functional disruption, 
which may be disassociated from hippocampal volume’s impact on memory.45 An imaging 
study demonstrated that damage to white matter fiber tracts within Papez’s memory circuit 
caused aberrant connectivity with hippocampal structures, which might contribute to 
aMCI.46 Nonetheless, our small MRI sample size might have limited our ability to observe 
differences in hippocampal volume and may have affected the results.
Following 16 weeks of antidepressant treatment, performance on a verbal delayed recall task 
declined in the h-OSA group. Taking into account potential practice effects, the worsening 
performance suggested a true cognitive deficit in h-OSA group. This result raises the 
important question of whether antidepressants influence the severity of OSA, which might, 
in turn, affect episodic memory. Several studies have examined the effectiveness of 
antidepressants as a drug treatment option for OSA. The rationale was that serotonin plays a 
critical role in maintaining upper airway patency during sleep, and antidepressants might 
increase upper airway dilator muscle tone, thus reducing its collapsibility during sleep in 
patients with OSA.47 Some showed that antidepressant treatment reduced OSA severity 
(AHI) compared to placebo while others reported that no benefits were observed.47 
Therefore, the use of citalopram or venlafaxine was not likely to have caused worsening of 
OSA. On the other hand, due to worsening verbal episodic memory despite successful 
treatment of depression in the h-OSA group, the presence of depression at baseline may 
have masked the impact of OSA on cognition. Therefore, screening for OSA in this type of 
patient has potentially important clinical utility.
Strengths and Limitations
To our knowledge, this is the first study that has explicitly examined the association between 
OSA, cognition, and brain structural abnormalities in older adults with aMCI and 
depression. In comparing changes in cognitive performance between the h-OSA group and l-
OSA group after depression was successfully treated, this study design allowed us to begin 
to disentangle the effects of confounding variables that are frequently present in patients 
with both depression and aMCI. Our findings add to the growing body of literature 
suggesting that a mixture of AD and microvascular pathologies may heighten one’s risks of 
progressive cognitive deterioration and developing dementia.48
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On the other hand, caution is needed for the interpretation of our preliminary findings due to 
several limitations. First, the gold standard diagnostic method for OSA is polysomnography 
(PSG). In this preliminary study, we used the STOP-Bang questionnaire to assess probability 
of moderate to severe OSA. A score of ≥ 5 was classified as h-OSA while a score of <5 was 
classified as l-OSA; this clinical classification led to strong associations with cognitive and 
MRI-derived variables. However, expanded studies using PSG to diagnose OSA are 
warranted. Other limitations included our small sample size and the lack of control for 
multiple statistical comparisons, thus increasing the likelihood of a Type-I error among our 
exploratory analyses.
CONCLUSIONS
In older adults with aMCI and depression, the presence of OSA was associated with 
microvascular damage and impaired verbal episodic memory, which are consistent with the 
existing literature on non-depressed and middle-aged OSA patients. One possibility is that 
by contributing to cerebral microvascular pathologies, OSA exacerbates progressive memory 
decline, despite successful treatment of depression. Therefore, cognitive deficits 
accompanying OSA may persist or progress if OSA is left untreated. Clinical trials are 
needed to determine whether OSA treatment can change the trajectory of cognitive 
deterioration in older adults who are at a high risk of developing dementia.
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